SEATTLE, Washington — February 2, 2026 — Leads & Copy — Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced the pricing of an underwritten offering expected to generate approximately $175 million before deductions.
The offering includes 39,576,088 shares of common stock priced at $3.79 per share. Select investors will receive pre-funded warrants for 6,598,046 shares at $3.789 per warrant. The offering is expected to close around February 3, 2026, pending standard closing conditions. All shares and warrants in the offering are being sold by Perspective Therapeutics.
Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital (a Citadel company), Affinity Asset Advisors, HBM Healthcare Investments, Ally Bridge Group and other healthcare investors participated in the financing.
Piper Sandler, UBS Investment Bank, Oppenheimer & Co., Truist Securities and LifeSci Capital are the joint book-running managers. Jones acted as financial advisor to Perspective Therapeutics for the offering.
Perspective Therapeutics plans to use the net proceeds to advance clinical development, invest in manufacturing facilities, and for general corporate purposes. A portion of the proceeds may be used for acquisitions, licensing, or investments in complementary products, technologies, or businesses, although there are no current commitments.
The securities are being offered under a registration statement on Form S-3, declared effective by the SEC on April 8, 2025. A final prospectus supplement will be filed with the SEC and is accessible at www.sec.gov.
Copies of the final prospectus supplement and accompanying prospectus can be obtained from Piper Sandler & Co., UBS Securities LLC, Oppenheimer & Co. Inc., Truist Securities, Inc., or LifeSci Capital LLC.
This announcement does not constitute an offer to sell or a solicitation to buy securities, nor will there be any sale of securities in any jurisdiction where such an offer, solicitation, or sale would be unlawful.
Perspective Therapeutics, Inc. is a radiopharmaceutical company developing cancer treatments, utilizing the alpha-emitting isotope 212Pb to target cancer cells. The company is also developing imaging diagnostics to personalize treatment and improve patient outcomes.
The company’s neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a trials in the U.S. Perspective Therapeutics is expanding its network of drug product candidate finishing facilities, supported by its 212Pb generator, to supply clinical trials and commercial operations.
Source: Perspective Therapeutics, Inc.
